Related Experiment Video
Updated: Jan 16, 2026
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.2K
Tumor Mutational Burden in Cervical Cancer as Potential Marker for Immunotherapy Responders
Magdalena Ewa Kowalkowska1,2, Katarzyna Kamińska3, Joanna Wojtysiak3
1Clinical Department of Oncological Gynecology, Oncology Centre in Bydgoszcz, 85-796 Bydgoszcz, Poland.
Cancers
|September 27, 2025
Summary
Tumor mutational burden (TMB) is common in cervical cancer, independent of stage or subtype. High TMB correlates with specific molecular profiles and comorbidities, aiding immunotherapy patient selection.
Area of Science:
- Oncology
- Genomics
- Biomarker Research
Background:
- Tumor mutational burden (TMB) shows promise as an immunotherapy biomarker in solid tumors.
- Its significance in cervical cancer requires further definition.
Purpose of the Study:
- To assess the genomic landscape and TMB profile in cervical cancer patients.
- To explore TMB associations with clinical features, HPV status, and treatment.
Main Methods:
- Retrospective analysis of 61 cervical cancer patients.
- Targeted next-generation sequencing for TMB calculation.
- Correlation analysis with clinical and molecular variables.
Main Results:
- High TMB (≥10 mut/Mb) observed in 59% of patients.
- TMB did not correlate with FIGO stage, histology, or HPV 16/18.
- Higher TMB linked to nodal involvement, diabetes, and HPV52 infection.
- PIK3CA and ARID1A were frequently mutated.
Conclusions:
- High TMB is prevalent in cervical cancer, independent of stage or histology.
- TMB correlates with specific molecular and comorbidity profiles.
- TMB may aid patient stratification for immunotherapy.
